gastroparesis symptoms glp 1 GLP-1 Intolerance and Endoscopic Sleeve Options GLP-1 and Gastroparesis: Clinical Safety

This framework explains why some patients see dramatic improvements while others see modest changes

The body quickly builds a tolerance to it, meaning that after a few weeks or months, the same dose no longer produces the same appetite-suppressing effect

Thyroid 35 , 6978 (2025)

for example, GIP plus glucagon or a triagonist comprising GIP, GLP-1 and glucagon is also being developed for patients with obesity, diabetes or dyslipidaemia

Adenosine A(2A) receptor antagonists in Parkinsons disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued

While these mechanisms contribute to weight loss success, they can also result in gastrointestinal side effects, including nausea, constipation, and, importantly, diarrhea